Conference call scheduled for November 09, 2018 at 8:00 AM ET
NEW HAVEN, Conn., Nov. 02, 2018 — BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it will release its financial results for the third quarter ended September 30, 2018 on Friday, November 09, 2018. The Company will hold a conference call at 8:00 AM Eastern Time on Friday, November 09, 2018 to discuss the financial results and provide a business update.
CONFERENCE CALL & WEBCAST- Friday, November 9, 2018, 8:00 a.m. Eastern Time Domestic: 888-394-8218 International: 323-794-2588 Conference ID: 2305463 Webcast: https://public.viavid.com/index.php?id=131946 Replay – Available through December 9, 2018 Domestic: 844-512-2921 International: 412-317-6671 Conference ID: 2305463
About BioXcel Therapeutics, Inc. (BTI): BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.